Table 1 Relationship between UCA1 expression and clinical features of gastric cancer
From: LncRNA UCA1 promotes development of gastric cancer via the miR-145/MYO6 axis
Clinical features | Patients (n = 85) | UCA1 expression | X2 | P | ||
|---|---|---|---|---|---|---|
Low (n = 46) | High (n = 39) | |||||
Age | ≤ 60 | 47 | 25 (53.19%) | 22 (46.81%) | 0.036 | 0.849 |
> 60 | 38 | 21 (55.26%) | 17 (44.74%) | |||
Gender | Male | 50 | 26 (52.00%) | 24 (48.00%) | 0.219 | 0.640 |
Female | 35 | 20 (57.14%) | 15 (42.86%) | |||
Tumor size | ≤ 5 cm | 43 | 28 (65.12%) | 15 (34.88%) | 4.240 | 0.039 |
> 5 cm | 42 | 18 (42.86%) | 24 (57.14%) | |||
Metastasis | Absent | 43 | 29 (67.44%) | 14 (32.56%) | 6.222 | 0.013 |
Present | 42 | 17 (40.48%) | 25 (59.52%) | |||
Recurrence | Absent | 40 | 27 (67.50%) | 13 (32.50%) | 5.449 | 0.020 |
Present | 45 | 19 (42.22%) | 26 (57.78%) | |||